Desidustat

ApprovedSmall molecule

ZZydus Lifesciences Limited

Desidustat is one of 93 small molecule programs targeting Anemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

COVID-19Active, not recruiting

Chronic Kidney DiseaseActive, not recruiting

AnemiaPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Desidustat

ZZydus Lifesciences Limited

Approved

1 2

Biaxin

AbbVie

Preclinical

2 3

Singulair

AstraZeneca

Preclinical

1 4

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 5

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

Rayaldee

OOrganon and Co

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 9

Achromycin V

WWyeth-Lederle Vaccines

Statins

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anemia3 trials

Desidustat in the Treatment of Chemotherapy Induced Anemia

Completed·ZZydus Lifesciences Limited·Phase 1·NCT04667533·24 enrolled

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Completed·ZZydus Lifesciences Limited·Phase 3·NCT04215120·392 enrolled

Desidustat in the Treatment of Anemia in CKD

Completed·ZZydus Lifesciences Limited·Phase 3·NCT04012957·588 enrolled

Chronic Kidney Disease1 trial

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

Recruiting·ZZydus Lifesciences Limited·Phase 4·NCT05515367·1,004 enrolled

COVID-191 trial

Desidustat in the Management of COVID-19 Patients

Completed·ZZydus Lifesciences Limited·Phase 2·NCT04463602·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Desidustat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Desidustat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Desidustat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zydus Lifesciences Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: ZZydus Lifesciences Limited

Desidustat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anemia3 trials

Chronic Kidney Disease1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News